The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023. The ...
PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...
PanGIA Biotech, Inc. ("PanGIA") announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine Learning Assay Detects Prostate Cancer," (1) demonstrating clinical validation ...
TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...
Harbinger Health, a Cambridge biotech spun out of Flagship, says it has locked in $100 million in new financing as it races ...
MethylScan is a low-cost blood test that detects cancers and organ diseases by analyzing DNA methylation, improving early diagnosis, and identifying disease origin.
Former Castle Biosciences SVP brings proven diagnostic commercialization and reimbursement leadership to NovaScan’s ...
A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common ...
Caris POA members advance precision medicine through collaborative research aimed at improving clinical outcomes for cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results